Published in the Journal of Clinical Oncology, a review paper authored by a multidisciplinary group of international experts in DNA Damage Response (DDR) and PARP inhibition
Oncology
Moving from PARP Inhibition to Targeting DNA Repair and DDR in Cancer Therapy
Dr Judith Balmaña
Dr Rebecca Dent
Prof. Simon Boulton
Prof. Sibylle Loibl
Prof. Eric Pujade-Lauraine
Prof. Charlie Gourley
Dr Violeta Serra
Prof. Jonathan A. Ledermann
Publication Date
Sep 2021
Dr Judith Balmaña has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca.
Dr Rebecca Dent has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Eisai, Genentech, Lilly, Merck, Novartis, Pfizer and Roche.
Prof. Simon Boulton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
Artios Pharma Ltd.
Prof. Sibylle Loibl has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Amgen, Novartis, Pfizer and Roche.
Prof. Eric Pujade-Lauraine has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Pfizer, Roche and Tesaro.
Prof. Charlie Gourley has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Apera, Clovis, MSD, Nucana, Novartis, Roche, Sierra Oncology and Tesaro.
Dr Violeta Serra has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca and Tesaro.
Prof. Jonathan A. Ledermann has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:
AstraZeneca, Clovis, Cristal Therapeutics, Pfizer, Roche and Seattle Genetics.
Programme summary
-
Duration
10 MIN
-
Downloadable resources
Yes
-
DOWNLOAD THE SLIDES
-
Language(s)
Other programmes of interest
Podcast
Oncology
HR+/HER2- metastatic breast cancer: Best practices in molecular testing and targeted therapy
Optimising precision medicine for improved patient outcomes
Experts
Dr Roberto Salgado, Assoc. Clinical Professor Rena CallahanEndorsed by
-
Downloadable
Resources -
26 MIN
-
Mar 2025
Conference update
Oncology
Current and future treatment strategies for patients with ER+/HER2- early breast cancer
A closer look at the evolving treatment landscape
Experts
Prof. Michael Gnant, Prof. Giuseppe Curigliano-
Downloadable
Resources -
4 MIN
-
Mar 2025
Video
Oncology
LEAP-012 publication snapshot
Expert insights on multimodal treatment for intermediate hepatocellular carcinoma (HCC)
Experts
Prof. Arndt VogelEndorsed by
-
Downloadable
Resources -
5 MIN
-
Mar 2025
Conference update
Oncology
ER+ metastatic breast cancer: Highlights from the 13th APBCS Satellite Symposium
Medical experts discuss treatment strategies and sequencing after ET + CDK4/6i for ER+/HER2- metastatic breast cancer
Experts
Prof. Shaheenah Dawood, Prof. Heather McArthur, Prof. Javier Cortés, Prof. Frédérique Penault-Llorca-
Downloadable
Resources -
5 MIN
-
Feb 2025
Podcast
Hemostasis and bleeding disorders Oncology
Σειρά podcast για τη διαχείριση της θρόμβωσης
Αναλύσεις από καταξιωμένους ειδικούς ιατρούς. Πλοηγηθείτε στις καρτέλες για να επιλέξετε ένα επεισόδιο podcast
Experts
Prof. Dimitrios Tsakiris, Prof. Michael Nagler, Dr Lars Asmis, Prof. Jerzy Windyga-
Downloadable
Resources -
27 MIN
-
Feb 2025
Conference update
Oncology
ESMO Virtual Plenary: Final OS results from the phase III TROPION-Breast01 trial
How will the latest Dato-DXd data impact treatment strategies for HR+/HER2− mBC?
Experts
Prof. François-Clément Bidard, Dr Barbara Pistilli-
5 MIN
-
Feb 2025